Regulus Therapeutics — Investor Presentation (October 2021)
36 slides from Regulus Therapeutics's investor presentation, Oct 18, 2021
Slide 1: Corporate Presentation - October 2021
Corporate Presentation - October 2021 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, including
Slide 3: Regulus Investment Highlights
Regulus Investment Highlights Leading microRNA Co leveraging novel technology into first-in-class therapeutics Expertise in microRNA biology/oligo chemistry based on company founding via JV between Ionis & Alnylam Platform optimized to deliver oligonucleotide therapies to the kidney Clinical pipelin
Slide 4: Innovative Pipeline: Primary Focus on Kidney Diseases
Innovative Pipeline: Primary Focus on Kidney Diseases Target Validation Lead Optimization IND enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome lademirsen* ADPKD** RGLS8429 Research Programs Other Research Programs*** *Formerly RG-012 **Autosomal Dominant Polycystic Kidney Disease *** CNS,
Slide 5: Lademirsen (RG-012): Alport Syndrome
Clinical demonstration of desired kidney exposure & binding of target, miR-21 Lademirsen (RG-012): Alport Syndrome Partnered with Sanofi Achieved $10m milestone in 2020 Regulus eligible to receive $25M milestone upon successful completion of Phase 2 Attractive safety profile to date: Chronic treatme
Slide 6: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Orphan disease and high unmet medical need Kidney Function Decline by Age The Underlying Pathology Mutation of either Pkd1 or Pkd2 genes causes formation and proliferation of fluid-filled cysts in the kidneys leading to loss of kidney function ove
Slide 7: ADPKD: Orphan disease and high unmet medical need
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Orphan disease and high unmet medical need 85% 160K patients with Pkd1 mutation diagnosed individuals in U.S. Patient population 50% patients develop ESRD by age 60 Health Burden $3.8B+ estimated annual cost of renal replacement therapy in U.S.1 1
Slide 8: Limitations of Standard of Care: Jynarque
Jynarque® (tolvaptan, vasopressin V2 antagonist) – FDA approved April 2018 Boxed warning due to potentially fatal liver injury & failure requiring transplant REMS program with restricted distribution & ongoing liver monitoring in patients Despite limitations, 2020 sales were $694M in US (2021 est. $
Slide 9: ADPKD Pathology
ADPKD Pathology Increased miR-17 expression Represses target gene expression (Pkd1 and Pkd2) Decreases PC1 and PC2 protein levels Mutations in Pkd1 and Pkd2 genes
Slide 10: ADPKD Pathology: Inhibiting miR-17
ADPKD Pathology Inhibits miR-17 function De-represses Pkd1 and Pkd2 gene expression Increases PC1 and PC2 protein levels Mutations in Pkd1 and Pkd2 genes Treatment with anti-miR17 uELV = urinary exosome-like vesicle Significant increase in PC1 and PC2 measured in uELVs
Slide 11: Pathway to Target Validation
Pathway to Target Validation Disease Association Genetic Validation Pharmacologic Validation Biomarker Validation
Slide 12: miR-17 is Upregulated in ADPKD models
miR-17 is Upregulated in ADPKD models Mouse kidney cysts & human ADPKD cyst cells Human Kidney Samples In-situ hybridization Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 Normal Human Kidney ADPKD Kidney miR-17 probe miR-17 probe Control probe Control probe Mouse Kidney Samples qPCR analysis Nor
Slide 13: miR-17 Directly Binds Pkd1 & Pkd2 Genes Mediating ADPKD
miR-17 Directly Binds Pkd1 & Pkd2 Genes Mediating ADPKD 3’UTRs of Pkd1 and Pkd2 contain conserved miR-17 binding sequences miR-17 mimic represses Pkd1 and Pkd2 in mouse collecting duct (IMCD3) cells PNAS 2013 June;110(26): 10765-10770 WT: wildtype 3’UTR MT: mutated 3’UTR Pkd1: 3’UTR conserved bindin
Slide 14: Kidney-specific Knockdown of miR-17~92 Cluster Attenuates disease
Kidney-specific Knockdown of miR-17~92 Cluster Attenuates disease in ADPKD mouse model (Pkd1F/RC) Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 MRI Imaging c: Serum Creatinine d: % Proliferation based on number of pHH3+ proliferating cyst epithelial cells Disease Association Genetic Validation P
Slide 15: Restoration of Pkd2 Expression is Disease-Modifying in ADPKD
Dong et al, Nature Genet 2021; https://doi.org/10.1038/s41588-021-00946-4 Tamoxifen treatment starting at 13w increases PC2 expression in genetically-engineered mouse model of ADPKD and reverses cyst formation Restoration of pkd2 Expression is Disease-Modifying in ADPKD Recent Publication Showed Dis
Slide 16: First Gen Compound (RGLS4326) confers efficacy in Pkd1F/RC mouse model
First Gen Compound (RGLS4326) treatment confers efficacy in Pkd1F/RC mouse model of ADPKD Lee et al. (2021) PKD-Connect; Poster Presentation KW = kidney weight; BW = Body weight Pkd1F/RC mice were dosed s.c. with RGLS4326 or Control Oligo at 20 mg/kg on post-natal day (P)8, 10, 12 and 15 and sacrifi
Slide 17: First Gen Compares Favorably to Standard of Care
15w (sacrifice) First Gen Compares Favorably to Standard of Care Efficacy in the Pcy/DBA Mouse Model Age: 6w 14w Pcy/DBA: Tolvaptan (Chow; ad libitum) RGLS4326 (QW) Lee et al., (2019)10:4148 Nat. Comm. Disease Association Genetic Validation Pharmacologic Validation Biomarker Validation
Slide 18: First Gen Slows Cystic Expansion
First Gen Slows Cystic Expansion Efficacy in the Pcy/DBA mouse model Stabilization Reduction Reduction Magnetic Resonance Imaging Lee et al., (2019)10:4148 Nat. Comm. Changes in body-weight adjusted total kidney volume (bwTKV) from baseline at week 8, 11 and 14 was significantly reduced after RGLS43
Slide 19: Urinary Biomarker Assay Can Detect PC1 and PC2 in Humans
Urinary Biomarker Assay Can Detect PC1 and PC2 in Humans Protein levels correlated with disease severity Lower levels of PC1 and PC2 are associated with disease severity based on increased kidney size Preliminary analysis support sample size (n=9) sufficient to detect ~45% and ~70% increase in PC1 a
Slide 20: First Gen treatment Increases Polycystin Levels In Vitro
First Gen treatment Increases Polycystin Levels In Vitro Achieved by binding miR-17 and derepressing Pkd1 and Pkd2 Gene Expression (RNA) (Protein) Lee et al. (2021) PKD-Connect; Poster Presentation Disease Association Genetic Validation Pharmacologic Validation Biomarker Validation
Slide 21: First Gen Demonstrated Significant Increase in Key Biomarkers in Patients
First Gen Demonstrated Significant Increase in Key Biomarkers in Patients with ADPKD Lee et al. (2021) PKD-Connect; Poster Presentation Significant increase in urinary PC1 and PC2 were observed at the end of the study (D71) compared to baseline (p=0.004 and p=0.026, respectively, based on paired t-t
Slide 22: First Gen (RGLS4326) Summary
First Gen (RGLS4326) Summary Statistically significant increase in key biomarkers (polycystin 1 & 2) demonstrated in patients with ADPKD in short term study at 1 mg/kg Polycystin levels inversely correlated with disease severity and restoring expression has been shown to reverse disease in animal mo
Slide 23: Next Gen (RGLS8429) Overview
Next Gen (RGLS8429) Overview
Slide 24: RGLS8429: Next Generation Anti-miR-17 for ADPKD
RGLS8429: Next Generation Anti-miR-17 for ADPKD Next Steps: IND-enabling activities near complete with IND and initiation of Phase 1 expected in Q2 2022 Completed: non-GLP toxicity studies at 2-3x higher dose levels with no similar dose-limiting toxicity signs Succeeded in designing new compound wit
Slide 25: RGLS8429 does not Inhibit AMPA Glutamate Receptors
RGLS8429 does not Inhibit AMPA Glutamate Receptors (AMPA-R): Absence of CNS-like Toxicities seen with RGLS4326 *[3H] AMPA ligand binding to synaptic membranes from rat cerebral cortex. Whole-cell patch-clamp studies in HEK293 cells overexpressing rGluA1 or rGluA2 in response to 3mM Glutamate. Unpubl
Slide 26: RGLS8429 Significantly More Tolerable than RGLS4326 in Toxicity Studies
Next-gen RGLS8429 Shown to be Significantly More Tolerable than RGLS4326 in Preclinical Toxicity Studies Dotted Lines Indicate Cumulative Exposure with No CNS-like adverse events
Slide 27: RGLS8429 has Similar In-Vitro Potency to miR-17 Compared to RGLS4326
RGLS8429 has Similar In-Vitro Potency to miR-17 Compared to RGLS4326 Mouse Cells Human Cells Normal Kidney Cells ADPKD Cells RGLS4326 IC50=77nM* RGLS8429 IC50=168nM *Lee et al., (2019)10:4148 Nat. Comm. RGLS4326 IC50=48nM RGLS8429 IC50=56nM RGLS4326 IC50=93nM RGLS8429 IC50=82nM RGLS4326 IC50=17nM RG
Slide 28: RGLS8429 has Similar PK profile Compared to RGLS4326
RGLS8429 has Similar PK profile Compared to RGLS4326 with Preferential Kidney Exposure and Long Half-Life in Tissue *Lee et al., (2019)10:4148 Nat. Comm. *
Slide 29: RGLS8429 has similar PD profile compared to RGLS4326
RGLS8429 has similar PD profile compared to RGLS4326 *Lee et al., (2019)10:4148 Nat. Comm. * *
Slide 30: RGLS8429 has similar efficacy in Pkd1F/RC mouse model
RGLS8429 has similar efficacy in Pkd1F/RC mouse model of ADPKD compared to RGLS4326 Pkd1F/RC mice were dosed SC with PBS or 20 mg/kg of designated oligos on post-natal days (P)8, 10, 12, 15 and euthanized at P18 PBS Control Oligo RGLS8429 RGLS4326
Slide 31: RGLS8429 Demonstrated Potent Efficacy as low as 1mg/kg
RGLS8429 Demonstrated Potent Efficacy in Pkd1F/RC mouse model of ADPKD as low as 1mg/kg Pkd1F/RC mice were dosed SC with PBS, control oligo at 20 mg/kg, or RGLS8429 at 1, 5 or 20 mg/kg on post-natal days (P)8, 10, 12, 15 and euthanized at P18. Another group of mice were dosed SC with RGLS8429 at 20m
Slide 32: RGLS8429 Combined with Tolvaptan Demonstrated Enhanced Efficacy
RGLS8429 Dosed in Combination with Tolvaptan in Pcy/DBA mouse model Demonstrated Enhanced Overall Efficacy Profile* Tolvaptan is the only approved therapy for patients with ADPKD Market Penetration has been slow due to significant warnings and monitoring as well as overall tolerability Anti-miR17 th
Slide 33: RGLS8429 Proposed Clinical Program
RGLS8429 Proposed Clinical Program
Slide 34: Proposed Interleaf Design Enables Rapid Path to Proof-of-Mechanism
Proposed Interleaf Design Enables Rapid Path to Potential Proof-of- Mechanism in Patients with APDKD 0.5 mg/kg 4.0 mg/kg 8.0 mg/kg 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg Single Dose Arm 2.0 mg/kg Multiple Dose Arm Healthy Volunteers 8 / cohort Single Dose with 14day f/u Randomized 3:1 Safety and PK ADPKD Pat
Slide 35: Anticipated Milestones
Anticipated Milestones Catalyst Potential Timing Pre-IND Meeting for next-gen RGLS8429 Q4 2021 IND Submission and Initiation of Phase 1 Study for RGLS8429 Q2 2022 Top-line Data from First Cohort of Patients in Phase 1b MOA Study Early 2023
Slide 36: Corporate Presentation- October 2021
Corporate Presentation- October 2021
Regulus Therapeutics — Investor Presentation (October 2021) on 6ix